Drug Trial Failure Continues to Sting Kamada on Wall Street

Drug Trial Failure Continues to Sting Kamada on Wall Street

Demandware Inc (NYSE:DWRE), Senomyx Inc. (NASDAQ:SNMX) and Gogo Inc (NASDAQ:GOGO) are starting off the week strong and are today’s top gainers midday. The losers are dELiA*s, Inc. (NASDAQ:DLIA), QuickLogic Corporation (NASDAQ:QUIK) and Kamada Ltd (NASDAQ:KMDA).

Play Quizzes 4

Soros Picks Senomyx, Gogo Soar

Demandware Inc (NYSE:DWRE) is today’s top gainer, its price surging +10.94%. A Julian Robertson holding, the e-commerce solutions provider is up +5.19% since reporting results on May 6th.

Maverick Capital Slides 22.9% In Q1, Short Bets Yield Positive Returns [Exclusive]

investor 1652197064Maverick Capital's flagship hedge fund lost -22.9% in the first quarter of 2022 according to a copy of the firm's quarterly update, which ValueWalk has been able to review. The firm's flagship fund, Maverick Fundamental Hedge, accounts for $3.7 billion of the group's $8.1 billion of assets under management. Even after losses in the first Read More

Following Demandware on this Monday’s list of midday gainers is Senomyx Inc. (NASDAQ:SNMX), up +10.38%. The company announced the two-year extension of an agreement with Pepsi – likely the reason for the price surge of this George Soros pick.

Last up is Gogo Inc (NASDAQ:GOGO), which got a +9.28% boost on the stock market today. UBS upgraded its rating of the in-flight telecommunications provider from neutral to buy and also set its target price at $26. Soros added Gogo to his portfolio in Q1.

Kamada Falls

dELiA*s, Inc. (NASDAQ:DLIA) slipped -8.88% midday today. The retailer has been in the Tiger Global portfolio for two quarters.

The share price of QuickLogic Corporation (NASDAQ:QUIK) -6.81% by midday, despite having started off strong this morning. George Soros initiated a position in QUIK during the first quarter of 2014.

Also on the losing end of the market this Monday is Kamada Ltd (NASDAQ:KMDA), down -6.50%. The Israeli drugmaker announced that one of its products had failed a key trial last week, and its stock continues to suffer the fall-out. Billionaire John Paulson has a position in the company.

Updated on

No posts to display